Our top pick for
Building a portfolio
Inventiva S.A is a biotechnology business based in the US. Inventiva S-A shares (IVA) are listed on the NASDAQ and all prices are listed in US Dollars. Inventiva S-A employs 88 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$9.01 - $19.06|
|50-day moving average||$14.14|
|200-day moving average||$14.08|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.32|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$5.3 million|
|Gross profit TTM||$4.4 million|
|Return on assets TTM||-20.82%|
|Return on equity TTM||-44.06%|
|Market capitalisation||$518.7 million|
TTM: trailing 12 months
There are currently 208,740 Inventiva S-A shares held short by investors – that's known as Inventiva S-A's "short interest". This figure is 14.8% up from 181,840 last month.
There are a few different ways that this level of interest in shorting Inventiva S-A shares can be evaluated.
Inventiva S-A's "short interest ratio" (SIR) is the quantity of Inventiva S-A shares currently shorted divided by the average quantity of Inventiva S-A shares traded daily (recently around 38371.323529412). Inventiva S-A's SIR currently stands at 5.44. In other words for every 100,000 Inventiva S-A shares traded daily on the market, roughly 5440 shares are currently held short.
However Inventiva S-A's short interest can also be evaluated against the total number of Inventiva S-A shares, or, against the total number of tradable Inventiva S-A shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inventiva S-A's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Inventiva S-A shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Inventiva S-A shares, roughly 0 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Inventiva S-A.
Find out more about how you can short Inventiva S-A stock.
We're not expecting Inventiva S-A to pay a dividend over the next 12 months.
Over the last 12 months, Inventiva S-A's shares have ranged in value from as little as $9.01 up to $19.0636. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inventiva S-A's is 0.9433. This would suggest that Inventiva S-A's shares are less volatile than average (for this exchange).
Inventiva S. A. , a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis.
Everything we know about the Talaris Therapeutics IPO, plus information on how to buy in.
Everything we know about the Sagimet Biosciences IPO, plus information on how to buy in.
Everything we know about the Zenvia IPO, plus information on how to buy in.
Everything we know about the Grove IPO, plus information on how to buy in.
Everything we know about the Pasithea Therapeutics IPO, plus information on how to buy in.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.